This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
by Sweta Killa
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
Company News for Dec 15, 2020
by Zacks Equity Research
Companies In The News Are: BA, ALXN, AZN, CVAC, GOOGL.
Vaccines Get to America, but Congressional Relief Lacking
by Mark Vickery
Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down.
Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion
by Zacks Equity Research
Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.
Wall Street Surges on COVID-19 Vaccine Approval
by Zacks Equity Research
Wall Street Surges on COVID-19 Vaccine Approval.
Historic Day for Pfizer (PFE), Covid-19 Vaccine
by Mark Vickery
With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.
AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion
by Zacks Equity Research
AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.
Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $120.98, moving +1.78% from the previous trading session.
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
by Zacks Equity Research
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study
by Zacks Equity Research
Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.
Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag
by Zacks Equity Research
The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.
Should Value Investors Consider Alexion (ALXN) Stock Now?
by Zacks Equity Research
Let's see if Alexion Pharmaceuticals, Inc. (ALXN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection
by Zacks Equity Research
The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.
How Will Biotech ETFs React to These Q3 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More
by Zacks Equity Research
Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.
Stock Market News for Oct 30, 2020
by Zacks Equity Research
Wall Street closed higher on Thursday recovering some lost ground of previous day's rout.
Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.
Alexion Pharmaceuticals (ALXN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 25.10% and 11.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Horizon (HZNP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.
HCA Healthcare (HCA) Q3 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results reflect decline in admissions, partly offset by higher revenues.
Trevena (TRVN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.
HCA Healthcare (HCA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter 2020 results are likely to reflect higher revenues owing to the gradual rise in patient volumes following the easing of government restrictions.
Alexion Pharmaceuticals (ALXN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.